Diversified Healthcare Trust vs Sabra Health Care REIT
DHC and SBRA side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DHC and SBRA compare
Sabra Health Care REIT is the larger company, worth 2.6 times as much as Diversified Healthcare Trust ($5.0B against $1.9B).
Sabra Health Care REIT grew revenue faster over the last twelve months (17.3% versus −1.5% for Diversified Healthcare Trust).
Sabra Health Care REIT keeps more of each dollar of sales as profit, with a net margin of 7.6% compared with −17.7% at Diversified Healthcare Trust.
Both pay dividends: Diversified Healthcare Trust yields 0.50% and Sabra Health Care REIT 6.1%.
Sabra Health Care REIT scores higher on the StockData Score (7 against 1 for Diversified Healthcare Trust), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DHC | SBRA |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $5.0B |
| Share price | $7.97 | $19.74 |
| Change, 1 year | 91.1% | 14.6% |
| Change, 5 years | 123% | 32.2% |
| Beta (5Y) | 1.09 | 0.48 |
| Employees | 600 | 58 |
| StockData Score | ||
| Total score | 1 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 0 | 0 |
| Dividend score | 1 | 3 (better) |
| Valuation | ||
| P/E | – | 75.9× |
| P/S | 1.3× (better) | 5.9× |
| P/B | 1.2× (better) | 1.8× |
| EV/EBITDA | 14.5× | 12.5× (better) |
| Fair value | $4.45 | $12.68 |
| Margin of safety | −78.9% | −55.7% (better) |
| Growth | ||
| Revenue growth (TTM) | −1.5% | 17.3% (better) |
| Revenue growth, 5Y average | −1.2% | 5.3% (better) |
| Net income growth (TTM) | – | −64.1% |
| EPS growth (TTM) | – | −65.8% |
| EPS growth, 5Y average | – | −0.91% |
| Profitability | ||
| Net margin | −17.7% | 7.6% (better) |
| Return on equity | −15.5% | 2.4% (better) |
| Financial health | ||
| Altman Z-score | 1.13 | 1.25 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.50% | 6.1% (better) |
| Payout ratio | – | 455% |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | −26.0% | −2.3% (better) |
| Buyback yield | 0.06% | – |
| Shareholder yield | 0.56% | 6.1% (better) |
| Ownership | ||
| Held by institutions | 84.9% | 102% |
| Held by insiders | 15.2% | 1.9% |
| Insider net buying, 12 months | $97.8K (better) | −$4.5M |
| Short interest, % of float | – | 7.9% |
Go deeper
- DHC stock overview
- DHC income statement
- DHC valuation and score
- SBRA stock overview
- SBRA income statement
- SBRA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.